01—Abstract
Summary
Summary of the 10-K filed February 17, 2021. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company reported robust revenue growth of 10% in 2020, reaching $24.5 billiona, driven primarily by strong volume increases in key products like Trulicity, Taltz, and Verzenio, as well as contributions from its COVID-19 therapies.
Despite a decrease in gross margin percentage due to pricing pressures and increased rebates, the company saw a significant 34% increase in net income from continuing operations to $6.2 billionb. Key to this performance were strategic acquisitions, including Dermira and Loxo Oncology, bolstering its late-stage pipeline in areas like immunology and oncology. The company also highlighted significant investments in R&D, particularly for COVID-19 treatments, and provided forward-looking guidance for 2021 expecting continued revenue growth and earnings per share.
Lilly's strong market position and diverse product portfolio, coupled with ongoing pipeline development, position it for continued growth, although it remains subject to risks related to patent expirations, pricing pressures, and regulatory changes. The company's financial health appears solid, with a substantial increase in cash and cash equivalents and positive cash flow from operations. Lilly also continues to return value to shareholders through dividends and share repurchases.
However, investors should remain aware of the potential impact of patent expiries on products like Alimta and the ongoing scrutiny of pharmaceutical pricing by governments and private payers worldwide. The company's forward-looking statements indicate an expectation of continued growth, but also acknowledge the dynamic nature of the pharmaceutical market and the ongoing need for innovation and strategic adaptation.
02—Key points
Key Highlights
- Revenue increased by 10% to $24.5 billion in 2020, driven by volume growth in key products and COVID-19 therapies.
- Net income from continuing operations increased by 34% to $6.2 billion, despite a slight decrease in gross margin percentage.
- Significant R&D investments were made, notably for COVID-19 therapies, with a robust pipeline of approximately 45 candidates in clinical development or under regulatory review.
- The company completed strategic acquisitions of Dermira and Loxo Oncology, strengthening its portfolio in immunology and oncology.
- Positive cash flow from operations of $6.5 billion, and cash and cash equivalents increased to $3.7 billion by year-end 2020.
- The company expects 2021 revenue between $26.5 billion and $28.0 billion, including $1 billion to $2 billion from COVID-19 therapies, and EPS between $7.10 and $7.75.
- Products like Trulicity, Taltz, and Verzenio showed significant year-over-year revenue growth.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 17, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $24.54B$22.32B | +9.9% |
| Cost of Revenue | $5.48B$4.72B | +16.1% |
| Gross Profit | $19.06B$17.60B | +8.3% |
| R&D Expenses | $5.98B$5.59B | +6.8% |
| SG&A Expenses | $6.12B$6.21B | −1.5% |
| Interest Expense | $359.60M$400.60M | −10.2% |
| Net Income | $6.19B$8.32B | −25.5% |
| EPS (Basic) | $6.82$8.93 | −23.6% |
| EPS (Diluted) | $6.79$8.89 | −23.6% |
| Shares Outstanding (Basic) | 907.63M931.06M | −2.5% |
| Shares Outstanding (Diluted) | 912.50M935.68M | −2.5% |
05—Questions
Frequently Asked Questions
What were Eli Lilly's key revenue drivers in 2020?
Eli Lilly's revenue growth in 2020 was primarily driven by increased volume for key products such as Trulicity (type 2 diabetes and cardiovascular risk reduction), Taltz (immunology), and Verzenio (oncology). Additionally, the company generated significant revenue from its COVID-19 therapies, bamlanivimab, contributing to a 10% overall revenue increase.
What is the company's outlook for 2021?
For 2021, Eli Lilly projects total revenue between $26.5 billion and $28.0 billion, with an expectation of $1 billion to $2 billion in revenue from COVID-19 therapies. Earnings per share are forecasted to be in the range of $7.10 to $7.75, excluding acquisition and integration costs. Growth is anticipated to be fueled by volume increases across several key products.
What are the primary risks the company faces?
Key risks for Eli Lilly include the potential loss of intellectual property protection for major products, leading to generic competition and revenue decline (e.g., Alimta). The company also faces intense competition, pricing pressures from governments and private payers, regulatory challenges, and risks associated with its R&D pipeline, including the inherent uncertainty and high failure rate of drug development. The COVID-19 pandemic also presented operational and demand-related risks.
How did the Elanco Animal Health disposition affect the company?
In March 2019, Eli Lilly completed the disposition of its remaining ownership in Elanco Animal Health Incorporated. This move resulted in a gain of approximately $3.7 billion in the first quarter of 2019 and allowed Lilly to operate as a single business segment focused on human pharmaceutical products.
06—Continue